Five-Year watch: gene Therapy's lasting impact on inherited deafness

NCT ID NCT06696456

ENROLLING_BY_INVITATION Disease control Sponsor: Akouos, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 11, 2026 · Last updated Apr 13, 2026 · Updated 2 times

Summary

This study monitors people with genetic hearing loss who previously received an experimental gene therapy. Researchers will follow 30 participants for about five years total to check for any delayed side effects and see how long the treatment's benefits last. The goal is to understand the long-term safety and durability of this one-time gene therapy injection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OTOFERLIN GENE-MEDIATED HEARING LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19146, United States
Hospital Sant Joan de Déu

Esplugues de Llobregat, Barcelona, 08950, Spain
National Taiwan University Hospital

Taipei, Taiwan, (R.O.C), 100, Taiwan
University of Iowa

Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.

OTOFERLIN GENE-MEDIATED HEARING LOSS